Founding Network Members Will Accelerate
Access to Proof-of-Concept Data for Prospective Xenium Customers
Worldwide
PLEASANTON, Calif., Dec. 20,
2023 /PRNewswire/ -- 10x Genomics, Inc.,
(Nasdaq: TXG), a leader in single cell and spatial biology, today
announced the launch of its Xenium Catalyst Network, a global group
of technically qualified research institutions that will accelerate
access to Xenium proof-of-concept data for researchers worldwide.
The four founding members of the Xenium Catalyst Network will add
significant capacity for the company's Xenium Catalyst Program, a
technical access service launched earlier this year for prospective
customers.
"Since we launched the Xenium Catalyst Program, the customer
response has been off the charts," said Jim
Wilbur, Chief Commercial Officer at 10x Genomics. "We're now
thrilled to expand the program with four exceptional founding
network members. These collaborators are as eager and committed as
we are to providing a world-class experience and helping more
researchers see firsthand the power and performance of Xenium on
their own samples."
While many researchers can use the company's comprehensive menu
of in situ datasets, the Xenium Catalyst Network will support
researchers who require proof-of-concept data on specific samples
to aid in grant applications, funding requests and purchasing
decisions. Through the Catalyst Network, researchers can choose
from a broad menu of custom and curated gene panels to directly
experience Xenium's class-leading performance and high sensitivity
and specificity on their own samples.
The Xenium Catalyst Network is intended to replicate and
expand the best-in-class experience and data that researchers can
expect when running Xenium in their own labs. The founding Catalyst
Network Members are Macrogen Inc., K2bio, BioChain Institute Inc.,
and The McDonnell Genome Institute at Washington University School of Medicine. 10x
Genomics expects to add more research institutions to the Xenium
Catalyst Network in 2024.
K2bio
K2bio enables early-stage life science companies to develop the
next generation of innovative therapies. K2 is at the forefront of
single cell analysis, offering revolutionary solutions that enable
researchers to explore cellular complexity with unprecedented
precision.
"K2bio, a novel full service preclinical Contract Research
Organization (CRO), welcomes our partnership with 10x Genomics and
the Xenium Catalyst Network," said Kieron
Jones, CEO at K2bio. "Leveraging our experience in
translational services, we have chosen to be a part of the Xenium
Catalyst Network because the platform provides quality data for
rapid insight into the biology of complex tissues, which aids our
unified goal to provide cutting edge technologies and
services."
Macrogen, Inc.
Macrogen is a global leader in precision medicine with a mission
to predict and diagnose diseases, and present personalized
treatment through R&D based on genome big data and
collaboration with medical institutes.
"Single cell spatial transcriptome analysis using Xenium is
believed to be a new technology that adds spatial information to
existing single cell analysis," said Changhoon Kim, CEO at Macrogen. "We are very
honored to be a Catalyst Network member, as Macrogen has been
objectively recognized for its competitiveness as a single cell
leader. Macrogen plans to expand pharmaceutical services for new
drug screening using in situ single cell analysis and in the future
intends to provide global services for precise clinical diagnostic
solutions for incurable diseases including cancer."
BioChain Institute Inc.
BioChain Institute Inc. has engaged in the field of biological
sample analysis for more than 25 years, empowering top global
pharma and academic leaders. Its goal is to advance accurate
disease diagnosis and drug discovery by enabling its clients with a
series of products and services, from sample collection and
preparation to analysis, providing customers with complete
solutions.
"We are excited to take this leap into expanding our partnership
with 10x Genomics for providing single cell spatial services using
the 10x Genomics Xenium In Situ platform," said Vidyodhaya
(Vidya) Sundaram, VP of Business
Development at BioChain Institute Inc. "With this collaboration, we
aim to leverage 10x's extensive experience in translational
research and product development to provide cutting edge technology
globally."
The McDonnell Genome Institute at Washington University School of Medicine
The McDonnell Genome Institute is a world leader in the
fast-paced, constantly changing field of genomics. The McDonnell
Genome Institute has developed a highly efficient, scalable
research pipeline to provide a variety of functional genomics
options.
"Participating in the 10x Genomics Xenium Catalyst Network will
help us deliver state-of-the-art spatial genomics services," stated
Michael Heinz, Director of Research
Operations at the McDonnell Genome Institute. "This collaboration
provides our researchers with efficient pathways to acquire
essential proof-of-concept data – an important step in securing
grant funding or commercializing new technologies."
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on LinkedIn or
Twitter.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are subject
to the "safe harbor" created by those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will,""enable," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "see," "predict," "potential," "would," "likely,"
"seek" or "continue" or the negatives of these terms or variations
of them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s expectations regarding the continued growth,
performance, utility and expansion of our Xenium platform and
Xenium Catalyst Network. These statements are based on management's
current expectations, forecasts, beliefs, assumptions and
information currently available to management, and actual outcomes
and results could differ materially from these statements due to a
number of factors. The material risks and uncertainties that could
affect 10x Genomics, Inc.'s financial and operating results and
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release include
those discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in the company's most recently-filed 10-K and elsewhere
in the documents 10x Genomics, Inc. files with the Securities and
Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics, Inc. may make. Further, such
forward-looking statements may not accurately or fully reflect the
potential impact of adverse geopolitical and macroeconomic events,
difficulties selling in APAC, product capabilities and adoption
rates, international economic, political, legal, compliance, social
and business factors, such as the COVID-19 pandemic, inflation,
supply chain that may have on the business, financial condition,
results of operations and cash flows of 10x Genomics, Inc. The
forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in our
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing 10x Genomics, Inc.'s views as of any date subsequent
to the date of this press release.
Disclosure Information
10x Genomics, Inc. uses filings
with the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-xenium-catalyst-network-302020356.html
SOURCE 10x Genomics, Inc